Advice
Following an abbreviated submission.
Seretide 50 Evohaler is accepted for use within NHSScotland for the regular treatment of asthma where use of a combination of the long-acting beta agonist salmeterol and the inhaled corticosteroid fluticasone is appropriate for a child aged 4-12 years.
The acquisition cost of the combination product is less than for the individual components given by aerosol inhalation and for the combination given by Accuhaler?.
Download detailed advice25KB (PDF)
Medicine details
- Medicine name:
- Seretide 50 Evohaler (Salmeterol xinafoate 25mcg/fluticasone propionate 50mcg)
- SMC ID:
- 108/04
- Indication:
- Asthma
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 July 2004